

Head Injury update Committee meeting 10

Date: 22/04/2022

Location: Virtual meeting

Minutes: Final

Committee members present:		
Caroline Balson [CB]		(Present for notes 1 – 9)
Ian Bernstein [IB] – Chair		(Present for notes 1 – 9)
Emily Feilding [EF]		(Present for notes 1 – 9)
Adel Helmy [AH]		(Present for notes 1 – 9)
Catriona Jones [CJ]		(Present for notes 1 – 9)
Fiona Lecky [FL] – Topic adviser		(Present for notes 1 – 9)
Mark Lyttle [ML]		(Present for notes 1 – 9)
Virginia Newcombe [VN]		(Present for notes 1 – 9)
Curtis Offiah [CO]		(Present for notes 1 – 9)
Patrick O’Halloran [PO]		(Present for notes 1 – 9)
James Piercy [JP]		(Present for notes 1 – 8)
Gillian Richards [GR]		(Present for notes 1 – 9)
Matthew Wiles [MW]		(Present for notes 1 – 9)
Colin Williamson [CW]		(Present for notes 1 – 9)

Co-opted members present:		
Nick Brown [NB]	Advanced Paramedic Practitioner in Critical Care, London Ambulance Service NHS Trust	
Ibrahim Jalloh [IJ]	Consultant Neurosurgeon, Cambridge University Hospitals NHS Foundation Trust, Cambridge	

In attendance:		
Rupert Franklin [RF]	Guideline Commissioning Manager	(Present for notes 1 – 9)
Philip Williams [PW]	Finance Analyst	(Present for notes 1 – 9)
Sharangini Rajesh [SR]	Senior Systematic Reviewer	(Present for notes 1 – 9)
Julie Neilson [JN]	Senior Systematic Reviewer	(Present for notes 1 – 9)

Sharon Swain [SS]	Guideline Lead	(Present for notes 1 – 9)
David Wonderling [DW]	Head of Health Economics	(Present for notes 1 – 9)
Giulia Zuodar [GZ]	Project Manager	(Present for notes 1 – 9)

Apologies:	

1. Welcome and objectives for the meeting
<p>The Chair welcomed the Committee members and attendees to the tenth meeting on Head Injury (update). No apologies were announced.</p> <p>The Chair outlined the objectives of the meeting, which included the following:</p> <ul style="list-style-type: none"> • Presenting the evidence for Indications for imaging for sub-groups. • Presenting the health economic model for tranexamic acid • Reviewing the committee discussions for observation for people with head injury who are on anticoagulant or antiplatelet therapy and Direct access to imaging
2. Confirmation of matter under discussion, and declarations of interest
<p>The Chair confirmed that, for the purpose of managing conflicts of interest, the matters under discussion were Indications for imaging for subgroups, Tranexamic acid, Direct access to imaging and Observation for people with head injury who are on anticoagulant or antiplatelet therapy.</p>
3. Declarations of interest
<p>The Chair and a senior member of the Developer’s team confirmed that based on previously recorded declarations the following applies:</p> <p>FL is partially excluded from the Indications for imaging for subgroups review (anticoagulant or antiplatelet therapy). FL can stay in the meeting but not participate in the discussion of the recommendations on anticoagulant or antiplatelet therapy.</p> <p>FL is partially excluded from the tranexamic acid review. FL can stay in the meeting but not participate in the discussion of the recommendations.</p> <p>VN is partially excluded from the Observation for people with head injury who are on</p>

anticoagulant or antiplatelet therapy. VN can stay in the meeting but not participate in the discussion of the recommendations.

The Chair asked the committee to declare any new interests that have arisen since the last meeting.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Matthew Wiles	GC member	Publication of review article Management of traumatic brain injury: a narrative review of current evidence, https://doi.org/10.1111/anae.15608 , 2022	Specific Non-financial - professional and personal – direct	Partial exclusion. Tranexamic acid included in the scope of the guideline. The committee member will remain in the room for presentation of the evidence and may be asked to respond to specific questions from the committee regarding this topic but will not take part in drafting the recommendations.
Fiona Lecky		As co investigator I have had a grant awarded by the Canadian Institute of Health Research (PI Prof Kerstin de Wit) for the “Can-ScHan” study to investigate predictors of intracranial injury in patients with head injury taking DOAC. The study is still in the planning stage across Canada UK and Australia	Specific Non-financial - professional and personal – direct	Partial exclusion. Indications for selecting adults, children and infants with head injury for CT or MRI head scan, including people on anticoagulant or antiplatelet therapy, is included in the scope of the

				<p>guideline.</p> <p>The committee member will remain in the room for presentation of the evidence and may be asked to respond to specific questions from the committee regarding this topic but will not take part in drafting the recommendations.</p>
--	--	--	--	--

The Chair and a senior member of the Developer's team confirmed that based on the above declarations the following applies:

MW is partially excluded from the tranexamic acid review. MW can stay in the meeting but not participate in the discussion of the recommendations .

4. Minutes of the previous meeting

The Committee agreed that the minutes of the previous meeting were an accurate record of the meeting.

5. Evidence review: Indications for imaging for sub-groups

The Committee was given a presentation on the clinical and cost-effectiveness evidence on Indications for imaging for sub-groups.

FL was partially excluded from the Indications for imaging for subgroups review (anticoagulant or antiplatelet therapy). FL stayed in the meeting but did not participate in the recommendations on anticoagulant or antiplatelet therapy.

6. Committee discussion: Direct access to imaging

The Committee reviewed the Committee discussion on Direct access to imaging and edited the recommendation.

7. Health economic model: Tranexamic acid

The Committee discussed the health economic model and drafted recommendations.

FL and MW were partially excluded from the tranexamic acid review. FL and MW stayed in the meeting but did not participate in recommendations

8. Committee discussion: Observation for people on anticoagulant therapy

The committee reviewed the Committee discussion on observation for people on anticoagulant therapy.

VN was partially excluded from the Observation for people with head injury who are on anticoagulant or antiplatelet therapy. VN stayed in the meeting but did not participate in the recommendations.

9. Any other business

None.

Date of next meeting: 25 April 2022

Location of next meeting: Virtual meeting